19,000 Australians now using PBS subsidised anti-HIV drugs

25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking ...

Read more →

Decisions relating to the funded brands of some anti-retroviral treatments for HIV

20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...

Read more →

Proposal to award sole supply and change some anti-retroviral brands

16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...

Read more →

Rapid rise in anti-HIV PrEP pills linked to drop in condom use

7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...

Read more →

New medicine to help end the transmission of HIV

21 March 2018 - The Australian Government is taking a critical step in helping end the transmission of HIV infection in ...

Read more →

National PreP service would be cost effective, research finds

20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...

Read more →

Proposal relating to two HIV treatments (Tivicay and Kivexa)

9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...

Read more →

CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)

24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...

Read more →

CADTH recommends reimbursement of Truvada for PrEP

24 August 2016 - The recommendation comes with conditions. ...

Read more →

Brisbane sees 30% drop in HIV infection over 5 year period; HIV medicine Truvada still not on PBS

23 August 2016 - The combination HIV medicines that has led to a significant drop in the number of HIV cases ...

Read more →

HIV prevention drug Truvada won't be subsidised in Australia anytime soon

19 August 2016 - An expensive combination product that prevents people from getting HIV won't be funded by taxpayers in Australia ...

Read more →

Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered

15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients. ...

Read more →

Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)

2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...

Read more →

Funding PrEP for HIV prevention

5 July 2016 - Delays by NHS England will cost lives—it’s time to do the right thing. ...

Read more →

HIV-positive children and adolescents: additional benefit of rilpivirine not proven

1 April 2016 - Under the trade name Edurant, rilpivirine hydrochloride as single agent has been approved already since 2011 for ...

Read more →